Skip to main content
H

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,430 across all filing types
Latest filing 2026-04-12 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
关于使用闲置自有资金进行委托理财的公告
Regulatory Filings Classification · 0% confidence The document is an announcement by the board of a Chinese listed company regarding the use of idle self-owned funds (up to RMB 1 billion) to purchase short-term, low-risk bank wealth management products. It is a corporate treasury management notice, not a report of financial results, share issuance, board changes, dividends, proxies, or M&A. It does not involve raising new capital or changes in capital structure. There is no detailed financial report or Excel data; rather, it is a formal regulatory announcement of a financing/investment action using own funds. This falls outside the narrow specialized categories and is best classified under the fallback category “Regulatory Filings” (RNS).
2026-04-12 Chinese
关于拟续聘会计师事务所的公告
Regulatory Filings Classification · 1% confidence The document is a corporate announcement regarding the proposed reappointment of the company’s external auditing firm for the 2026 fiscal year. It does not contain an actual audit report (so it is not AR), and it is not an AGM presentation, financial results release, management appointments, or any other more specific category. It’s essentially a regulatory announcement of the auditor engagement. Therefore, it falls into the general regulatory announcements fallback category (RNS).
2026-04-12 Chinese
海思科医药集团股份有限公司2025年12月31日内部控制审计报告
Audit Report / Information Classification · 1% confidence The document is titled “内部控制审计报告” (Internal Control Audit Report) issued by ShineWing, a certified public accounting firm, presenting an audit opinion on the effectiveness of internal controls as of December 31, 2025. It is a standalone audit report, aligning with the definition of an audit report/information filing. It is not an annual report, earnings release, or simple announcement, but a formal audit opinion document.
2026-04-12 Chinese
2025年度内部控制自我评价报告
Governance Information Classification · 1% confidence The document is a standalone internal control self-assessment report (“内部控制自我评价报告”) prepared by the company’s board, detailing the company’s internal control objectives, organizational structure, risk control processes, and governance mechanisms. It is not an annual or quarterly financial statement, nor an audit report by external auditors, earnings release, or dividend notice. It provides detailed information on internal rules, control policies, and governance committees, matching the definition of Governance Information (CGR).
2026-04-12 Chinese
第五届董事会第三十七次会议决议公告
Regulatory Filings Classification · 1% confidence The document is an official announcement of the board of directors’ meeting resolutions (第5届董事会第37次会议决议公告) by a listed Chinese company. It lists board resolutions, voting results, and references to related materials published on CNINFO. It is not an investor presentation, earnings release, financial report itself, or a shareholder vote resolution (DVA), nor does it announce changes in board composition (MANG). There is no issuance of capital, dividends, or proxies. As it does not fit any of the more specific categories, it falls under the fallback category “Regulatory Filings (RNS).”
2026-04-12 Chinese
2025年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 1% confidence The document is a 'Summary Table of Non-operating Fund Occupation and Other Related Party Fund Transactions' for 2025. This type of disclosure is a standard regulatory requirement in Chinese capital markets (often filed alongside annual reports or audit reports) to ensure transparency regarding related-party transactions. Since it is a specific financial disclosure table rather than a full annual report, a management report, or a simple announcement, it falls under the category of Regulatory Filings (RNS) as it serves as a compliance document detailing specific financial data points. FY 2025
2026-04-12 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.